Regeneron Is A Phenomenal Growth Story; Buying The Current Dip Could Be A Wise Move [Seeking Alpha]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Seeking Alpha
Summary The phenomenal success of wet AMD and retinopathy treatment Eylea ($7.5 billion sales in 2019) has underpinned Regeneron's strong revenue growth in recent years. In less than a decade, Regeneron has grown from a minor biotech with a single commercialised drug to a potential pharma powerhouse. Collaboration with Sanofi around asthma drug Dupixent looks promising - Sanofi's CEO has claimed $10 billion in annual sales achievable (Regeneron earns 50% of all sales in US -.$1.8 billion in 2019). Regeneron's bottom line earnings are affected somewhat by high costs of development, but short term and long term the company looks a buy to me. Market turmoil is making investing tricky at present, and Regeneron stock is suffering; but pre-COVID19 it was close to breaking $500 - a reasonable fair value price for the stock. Investment Thesis Before COVID-19 sent the stock market into meltdown, Regeneron Pharmaceuticals ( REGN The gains were driven by a strong set of Q4 and FY19 results, main
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head [Forbes]Forbes
- Measuring Cross-Platform Ad Effectiveness Using A Single-Source [Forbes]Forbes
- Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaGlobeNewswire
- Neuraxpharm reports another year of sustained growth and international expansion [Yahoo! Finance]Yahoo! Finance
- Diabetics left without treatment as global rate of disease doubles [Financial Times (FT.com) (UK)]Financial Times
SNY
Analyst Actions
- 9/19/24 - Citigroup Inc.
SNY
Sec Filings
- 11/7/24 - Form SC
- 11/7/24 - Form 6-K
- 10/31/24 - Form 6-K
- SNY's page on the SEC website